BeOne Medicines AG
Research BeOne Medicines AG (6160.HK) on Bullrun: market cap HKD 332.77B, P/E 67.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6160.HK
- ExchangeHK
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 332.77B
- P/E67.0
- Financial periodQ2 2026
- RevenueUSD 1.71B
- Net incomeUSD 237.01M
- Free cash flowUSD 414.83M
- Gross margin89.8%
Valuation Snapshot
latest market cap is HKD 332.77B; P/E is 67.0.
Peer valuation comparison
Latest P/E is 66.96x versus a Healthcare sector median of 21.69x (208.7% above).
Latest P/E is 66.96x versus a Switzerland median of 20.29x (230.1% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 332.77B | 67.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BeOne Medicines AG's market cap?
BeOne Medicines AG's market capitalization is HKD 332.77B.
What is BeOne Medicines AG's P/E ratio?
BeOne Medicines AG's price-to-earnings (P/E) ratio is 67.0.
What does BeOne Medicines AG do?
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.